U.K. House of Commons committee demands more clinical-trial transparency

09/18/2013 | PharmaTimes (U.K.)

A House of Commons Science and Technology Committee report says too many clinical trials remain unregistered and unpublished, and the lack of transparency undermines public trust, slows medical progress and potentially puts patients at risk. The committee does not advocate uncontrolled release of patient-level data, but does urge stronger government action to facilitate sharing of raw clinical-trial data.

View Full Article in:

PharmaTimes (U.K.)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Global Medical Safety Director - Transcatheter Heart Valve
Edwards Lifesciences
Irvine, CA
Assistant General Counsel/Senior Corporate Counsel - Healthcare Law Group
Genentech
South San Francisco, CA
Compliance Manager/Sr. Compliance Manager- Auditing
Genentech
South San Francisco, CA
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC